Frankfurt — The European Medicines Agency (EMA) said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced a common blood pressure and heart drug with an impurity that could cause cancer. The alarm over the valsartan drug was first raised in July, prompting a global recall of affected pills. The EMA initially said the problem probably dated back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical in 2012. But N-nitrosodimethylamine, a probable human carcinogen, was also found in batches of valsartan made by Zhejiang Tianyu, although at much lower levels than in the case of Zhejiang Huahai, the EMA said in a statement. "EMA is working closely with international partners to review the impact of the NDMA detected in valsartan from Zhejiang Tianyu and will communicate as soon as additional information becomes available," the regulator said. The EMA has said there could be one extra case of cancer for every 5,000 patients that had taken ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00.